Quantitative assessment of the diagnostic role of mucin family members in pancreatic cancer: a meta-analysis

Wang, Shunda; You, Lei; Dai, Menghua; Zhao, Yuanhui

doi:10.21037/atm-20-5606

Cited by 12 publications

(9 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Here, PDAC was composed of abnormal and irregular duct structures, while the paratumor tissue was made up of regular pancreatic acini. Moreover, IHC staining of SMAD4 [17] (low expression in pancreatic cancer) and MUC5AC [18] (high expression in pancreatic cancer) further confirmed the results of H&E staining (Figure 5A). Although H&E and IHC staining can give a solid pathological information of PC section, they still suffered from the complex timeconsuming operation and restricted in vivo application.…”

Section: Intraoperative Clinicopathological Diagnosis Of Pc Sectionssupporting

confidence: 74%

An Enzyme‐Activatable Aggregation‐Induced‐Emission Probe: Intraoperative Pathological Fluorescent Diagnosis of Pancreatic Cancer via Specific Cathepsin E

et al. 2021

View full text Add to dashboard Cite

fidelity diagnosis is of great importance for follow-up treatment. [1] However, traditional histological hematoxylin and eosin (H&E) and immunohistochemistry (IHC) staining cannot realize intraoperative pathological diagnosis, [2] because of their inherent complicated operation protocols with time-consuming, let alone in vivo tracking of PC (Figure 1A). Although immune-fluorescence (IF)-based technologies [3] have facilitated some aspects of histological evaluation, the deadly aggregation-caused quenching (ACQ) effects and poor photostability of most commercial dyes make the readout fluorescent signal to be with low signal/noise (S/N) and poor stability. [4] Moreover, the uncontrollable nonspecific attachment of IF dyes to biological tissues may interfere with the distinction between tumor (T) tissues and paratumor (PT) tissues (Figure 1A). As a consequence, it is of great urgency to develop an efficient and early clinical tool for real-time and high-specificity in situ diagnosing of PC.Recently, the vigorous and robust aggregation-induced emission luminogens (AIEgens) have expanded the database of fluorescent probes with targeting events through aggregation process, available for real-time and in situ imaging with excellent photostability, high-resolution, and long-term tracking ability. [5] However, the current AIEgens probes are still not ideal due to the Pancreatic cancer (PC) is one of the most devastating malignant tumors. However, fluorescence probes for early clinical diagnosis of PC often encounter difficulties in accuracy and penetrability. In this work, an enzymeactivated aggregation-induced-emission (AIE) probe, QM-HSP-CPP, for highcontrast fluorescence diagnosis of PC is developed by monitoring specific overexpressed enzyme Cathepsin E (CTSE). The probe is composed of an AIE fluorophore QM-COOH (QM = quinoline-malononitrile), CTSE-triggered hydrophobic peptide (HSP), and hydrophilic biocompatible cell penetrating peptide (CPP). The CPP unit can well-modulate the molecular dispersion properties, giving initial fluorescence-off state in the aqueous biosystem, thus endowing high signal-to-noise ratio, and finally overcoming the poor targeting selectivity of traditional AIE probes. CPP can ensure cell/tissue penetrating ability, thus allowing on-site monitoring of endogenous CTSE in PC cells, tissues, and living animal models. When the QM-HSP-CPP probe is specifically cleaved by CTSE, it can generate AIE signals in situ with high-specificity and long-term tracking ability, and successfully achieve intraoperative diagnosis of human PC sections, tracking PC in heterotopic nude mice models. The CTSE-enzyme-triggered AIEgens' liberation strategy improves accuracy and addresses the penetration problem simultaneously, which can expand the database of multitudinous biocompatible AIE-active probes, especially for establishing intraoperative pathological fluorescent diagnosis.The ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/adma.202107444.

show abstract

Section: Intraoperative Clinicopathological Diagnosis Of Pc Sectionssupporting

confidence: 74%

An Enzyme‐Activatable Aggregation‐Induced‐Emission Probe: Intraoperative Pathological Fluorescent Diagnosis of Pancreatic Cancer via Specific Cathepsin E

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The expression levels of MUC1 and MUC5AC correlate significantly with the tumor grade of colorectal cancer and are therefore used as markers for assessing the prognosis of GC patients [ 78 , 79 ]. In pancreatic cancer, MUC1 can be detected in different stages and can indicate initiation and progression with good diagnostic accuracy [ 80 ]. MUC1 can also be used as a biomarker for pigeon-sensitive asthma patients and not just a negative predictor of the survival of patients with cancers of epithelial origin [ 81 ].…”

Section: Clinic Applicationmentioning

confidence: 99%

MUC1: Structure, Function, and Clinic Application in Epithelial Cancers

Chen

Zhu

Zhang

et al. 2021

IJMS

134

View full text Add to dashboard Cite

The transmembrane glycoprotein mucin 1 (MUC1) is a mucin family member that has different functions in normal and cancer cells. Owing to its structural and biochemical properties, MUC1 can act as a lubricant, moisturizer, and physical barrier in normal cells. However, in cancer cells, MUC1 often undergoes aberrant glycosylation and overexpression. It is involved in cancer invasion, metastasis, angiogenesis, and apoptosis by virtue of its participation in intracellular signaling processes and the regulation of related biomolecules. This review introduces the biological structure and different roles of MUC1 in normal and cancer cells and the regulatory mechanisms governing these roles. It also evaluates current research progress and the clinical applications of MUC1 in cancer therapy based on its characteristics.

show abstract

“…As such, targeting the aberrations occurring during glycosylation either in terms of the levels of expressions of proteins or the glycans (glycome; e.g., truncated O-glycans, increased branching and fucosylation of N-glycans, upregulation of specific proteoglycans and galectins, and increased O-GlcNAcylation [130]) may be beneficial for the identification of diagnostic and/or therapeutic targets [131] as well as for aiding in treatment decisions for PDAC [132]. Along this line, mucin, a highly glycosylated protein, could also be a potential biomarker [133]. The levels of expression of mucin were previously reported to be altered in the course of development and progression of PDAC [134].…”

Section: Proteomics-based Pdac Research: Techniques Samples and Sampl...mentioning

confidence: 99%

Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review

Vellan

Jayapalan

Yoong

et al. 2022

IJMS

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC), a highly aggressive malignancy with a poor prognosis is usually detected at the advanced stage of the disease. The only US Food and Drug Administration-approved biomarker that is available for PDAC, CA 19-9, is most useful in monitoring treatment response among PDAC patients rather than for early detection. Moreover, when CA 19-9 is solely used for diagnostic purposes, it has only a recorded sensitivity of 79% and specificity of 82% in symptomatic individuals. Therefore, there is an urgent need to identify reliable biomarkers for diagnosis (specifically for the early diagnosis), ascertain prognosis as well as to monitor treatment response and tumour recurrence of PDAC. In recent years, proteomic technologies are growing exponentially at an accelerated rate for a wide range of applications in cancer research. In this review, we discussed the current status of biomarker research for PDAC using various proteomic technologies. This review will explore the potential perspective for understanding and identifying the unique alterations in protein expressions that could prove beneficial in discovering new robust biomarkers to detect PDAC at an early stage, ascertain prognosis of patients with the disease in addition to monitoring treatment response and tumour recurrence of patients.

show abstract

Quantitative assessment of the diagnostic role of mucin family members in pancreatic cancer: a meta-analysis

Cited by 12 publications

References 79 publications

An Enzyme‐Activatable Aggregation‐Induced‐Emission Probe: Intraoperative Pathological Fluorescent Diagnosis of Pancreatic Cancer via Specific Cathepsin E

An Enzyme‐Activatable Aggregation‐Induced‐Emission Probe: Intraoperative Pathological Fluorescent Diagnosis of Pancreatic Cancer via Specific Cathepsin E

MUC1: Structure, Function, and Clinic Application in Epithelial Cancers

Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review

Contact Info

Product

Resources

About